A novel role for von Willebrand factor in the pathogenesis of experimental cerebral malaria

Blood

Volumn 127, Issue 9, 2016, Pages 1192-1201

  O'regan, Niamh ^a   Gegenbauer, Kristina ^a   O'sullivan, Jamie M ^a   Maleki, Sanaz ^b   Brophy, Teresa M ^a   Dalton, Niall ^a   Chion, Alain ^a   Fallon, Padraic G ^a   Grau, Georges E ^b   Budde, Ulrich ^c   Smith, Owen P ^d,e   Craig, Alister G ^f   Preston, Roger J S ^d,g   O'Donnell, James S ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ASKLEPIOS KLINIK ALTONA   (Germany)

^d National Children's Research Centre   (Ireland)

^e OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^f LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^g TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ANTIGEN; PEPTIDE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN MALARIA; CELL ACTIVATION; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; EXOCYTOSIS; EXPERIMENTAL CEREBRAL MALARIA; EXPERIMENTAL NEUROLOGIC DISEASE; IMMUNE RESPONSE; INNATE IMMUNITY; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PARASITEMIA; PATHOGENESIS; PLASMODIUM BERGHEI; PRIORITY JOURNAL; THROMBOCYTE COUNT; WILD TYPE; ANIMAL; BIOLOGICAL MODEL; BLOOD; C57BL MOUSE; COMPLICATION; HUMAN; MALARIA, CEREBRAL; METABOLISM; PARASITOLOGY; PATHOLOGY; PERMEABILITY; PROTEIN MULTIMERIZATION; THROMBOCYTOPENIA;

ANIMALS; ANTIGENS; BLOOD-BRAIN BARRIER; ENDOTHELIAL CELLS; HUMANS; MALARIA, CEREBRAL; MICE, INBRED C57BL; MODELS, BIOLOGICAL; PEPTIDES; PERMEABILITY; PLASMODIUM BERGHEI; PROTEIN MULTIMERIZATION; THROMBOCYTOPENIA; VON WILLEBRAND FACTOR;

EID: 84960386394     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-07-654921     Document Type: Article

References (78)

1. Murray CJ, Rosenfeld LC, Lim SS, et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet. 2012;379(9814):413-431.
2. Carter JA, Ross AJ, Neville BG, et al. Developmental impairments following severe falciparum malaria in children. Trop Med Int Health. 2005;10(1):3-10.
3. Mung'Ala-Odera V, Snow RW, Newton CR. The burden of the neurocognitive impairment associated with Plasmodium falciparum malaria in sub-saharan Africa. Am J Trop Med Hyg. 2004;71(2 Suppl):64-70.
4. Newton CR, Krishna S. Severe falciparum malaria in children: current understanding of pathophysiology and supportive treatment. Pharmacol Ther. 1998;79(1):1-53.
5. Taylor TE, Fu WJ, Carr RA, et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat Med. 2004;10(2):143-145.
6. Clark IA, Cowden WB, Rockett KA. The pathogenesis of human cerebral malaria. Parasitol Today. 1994;10(11):417-418.
7. Berendt AR, Tumer GD, Newbold CI. Cerebral malaria: the sequestration hypothesis. Parasitol Today. 1994;10(10):412-414.
8. Grau GE, de Kossodo S. Cerebral malaria: mediators, mechanical obstruction or more? Parasitol Today. 1994;10(10):408-409.
9. Craig A, Scherf A. Molecules on the surface of the Plasmodium falciparum infected erythrocyte and their role in malaria pathogenesis and immune evasion. Mol Biochem Parasitol. 2001;115(2):129-143.
10. Turner L, Lavstsen T, Berger SS, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-505.
11. Grau GE, Mackenzie CD, Carr RA, et al. Platelet accumulation in brain microvessels in fatal pediatric cerebral malaria. J Infect Dis. 2003;187(3):461-466.
12. Patnaik JK, Das BS, Mishra SK, Mohanty S, Satpathy SK, Mohanty D. Vascular clogging, mononuclear cell margination, and enhanced vascular permeability in the pathogenesis of human cerebral malaria. Am J Trop Med Hyg. 1994;51(5):642-647.
13. Mayadas TN, Wagner DD. von Willebrand factor biosynthesis and processing. Ann N Y Acad Sci. 1991;614:153-166.
14. Lenting PJ, Christophe OD, Denis CV. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood. 2015;125(13):2019-2028.
15. Nightingale T, Cutler D. The secretion of von Willebrand factor from endothelial cells; an increasingly complicated story. J Thromb Haemost. 2013;11(Suppl 1):192-201.
16. Hollestelle MJ, Donkor C, Mantey EA, et al. von Willebrand factor propeptide in malaria: evidence of acute endothelial cell activation. Br J Haematol. 2006;133(5):562-569.
17. Larkin D, de Laat B, Jenkins PV, et al. Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition. PLoS Pathog. 2009;5(3):e1000349.
18. Conroy AL, Phiri H, Hawkes M, et al. Endothelium-based biomarkers are associated with cerebral malaria in Malawian children: a retrospective case-control study. PLoS One. 2010;5(12):e15291.
19. Erdman LK, Dhabangi A, Musoke C, et al. Combinations of host biomarkers predict mortality among Ugandan children with severe malaria: a retrospective case-control study. PLoS One. 2011;6(2):e17440.
20. Phiri HT, Bridges DJ, Glover SJ, et al. Elevated plasma von Willebrand factor and propeptide levels in Malawian children with malaria. PLoS One. 2011;6(11):e25626.
21. de Mast Q, Groot E, Asih PB, et al. ADAMTS13 deficiency with elevated levels of ultra-large and active von Willebrand factor in P. falciparum and P. vivax malaria. Am J Trop Med Hyg. 2009;80(3):492-498.
22. Löwenberg EC, Charunwatthana P, Cohen S, et al. Severe malaria is associated with a deficiency of von Willebrand factor cleaving protease, ADAMTS13. Thromb Haemost. 2010;103(1):181-187.
23. de Mast Q, Groot E, Lenting PJ, et al. Thrombocytopenia and release of activated von Willebrand Factor during early Plasmodium falciparum malaria. J Infect Dis. 2007;196(4):622-628.
24. de Mast Q, de Groot PG, van Heerde WL, et al. Thrombocytopenia in early malaria is associated with GP1b shedding in absence of systemic platelet activation and consumptive coagulopathy. Br J Haematol. 2010;151(5):495-503.
25. Wassmer SC, Combes V, Candal FJ, Juhan-Vague I, Grau GE. Platelets potentiate brain endothelial alterations induced by Plasmodium falciparum. Infect Immun. 2006;74(1):645-653.
26. Wassmer SC, Lépolard C, Traoré B, Pouvelle B, Gysin J, Grau GE. Platelets reorient Plasmodium falciparum-infected erythrocyte cytoadhesion to activated endothelial cells. J Infect Dis. 2004;189(2):180-189.
27. Pain A, Ferguson DJ, Kai O, et al. Plateletmediated clumping of Plasmodium falciparuminfected erythrocytes is a common adhesive phenotype and is associated with severe malaria. Proc Natl Acad Sci USA. 2001;98(4):1805-1810.
28. Bridges DJ, Bunn J, van Mourik JA, et al. Rapid activation of endothelial cells enables Plasmodium falciparum adhesion to plateletdecorated von Willebrand factor strings. Blood. 2010;115(7):1472-1474.
29. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci USA. 1998;95(16):9524-9529.
30. Denis CV, André P, Saffaripour S, Wagner DD. Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factordeficient mice. Proc Natl Acad Sci USA. 2001;98(7):4072-4077.
31. Amante FH, Stanley AC, Randall LM, et al. A role for natural regulatory T cells in the pathogenesis of experimental cerebral malaria. Am J Pathol. 2007;171(2):548-559.
32. McGrath RT, McKinnon TA, Byrne B, et al. Expression of terminal alpha2-6-linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13. Blood. 2010;115(13):2666-2673.
33. O'Donnell JS, McKinnon TA, Crawley JT, Lane DA, Laffan MA. Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood. 2005;106(6):1988-1991.
34. Badirou I, Kurdi M, Legendre P, et al. In vivo analysis of the role of O-glycosylations of von Willebrand factor. PLoS One. 2012;7(5):e37508.
35. Mohlke KL, Purkayastha AA, Westrick RJ, et al. Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineagespecific expression of a glycosyltransferase. Cell. 1999;96(1):111-120.
36. Shida Y, Rydz N, Stegner D, et al. Analysis of the role of vonWillebrand factor, platelet glycoprotein VI-, and a2b1-mediated collagen binding in thrombus formation. Blood. 2014;124(11):1799-1807.
37. Pruss CM, Golder M, Bryant A, et al. Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models. Blood. 2011;117(16):4358-4366.
38. Suidan GL, Brill A, De Meyer SF, et al. Endothelial Von Willebrand factor promotes blood-brain barrier flexibility and provides protection from hypoxia and seizures in mice. Arterioscler Thromb Vasc Biol. 2013;33(9):2112-2120.
39. Noubade R, del Rio R, McElvany B, et al. von-Willebrand factor influences blood brain barrier permeability and brain inflammation in experimental allergic encephalomyelitis. Am J Pathol. 2008;173(3):892-900.
40. Baptista FG, Pamplona A, Pena AC, Mota MM, Pied S, Vigário AM. Accumulation of Plasmodium berghei-infected red blood cells in the brain is crucial for the development of cerebral malaria in mice. Infect Immun. 2010;78(9):4033-4039.
41. de Souza JB, Riley EM. Cerebral malaria: the contribution of studies in animal models to our understanding of immunopathogenesis. Microbes Infect. 2002;4(3):291-300.
42. Turner GD, Ly VC, Nguyen TH, et al. Systemic endothelial activation occurs in both mild and severe malaria. Correlating dermal microvascular endothelial cell phenotype and soluble cell adhesion molecules with disease severity. Am J Pathol. 1998;152(6):1477-1487.
43. Wassmer SC, Cianciolo GJ, Combes V, Grau GE. Inhibition of endothelial activation: a new way to treat cerebral malaria? PLoS Med. 2005;2(9):e245.
44. Fiedler U, Scharpfenecker M, Koidl S, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood. 2004;103(11):4150-4156.
45. Conroy AL, Lafferty EI, Lovegrove FE, et al. Whole blood angiopoietin-1 and -2 levels discriminate cerebral and severe (non-cerebral) malaria from uncomplicated malaria. Malar J. 2009;8:295.
46. Lovegrove FE, Tangpukdee N, Opoka RO, et al. Serum angiopoietin-1 and -2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African children. PLoS One. 2009;4(3):e4912.
47. Yeo TW, Lampah DA, Gitawati R, et al. Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proc Natl Acad Sci USA. 2008;105(44):17097-17102.
48. Crawley JT, de Groot R, Xiang Y, Luken BM, Lane DA. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood. 2011;118(12):3212-3221.
49. Cox D, McConkey S. The role of platelets in the pathogenesis of cerebral malaria. Cell Mol Life Sci. 2010;67(4):557-568.
50. Faille D, El-Assaad F, Alessi MC, Fusai T, Combes V, Grau GE. Platelet-endothelial cell interactions in cerebral malaria: the end of a cordial understanding. Thromb Haemost. 2009;102(6):1093-1102.
51. Skudowitz RB, Katz J, Lurie A, Levin J, Metz J. Mechanisms of thrombocytopenia in malignant tertian malaria. BMJ. 1973;2(5865):515-518.
52. McMorran BJ, Marshall VM, de Graaf C, et al. Platelets kill intraerythrocytic malarial parasites and mediate survival to infection. Science. 2009;323(5915):797-800.
53. Srivastava K, Cockburn IA, Swaim A, et al. Platelet factor 4 mediates inflammation in experimental cerebral malaria. Cell Host Microbe. 2008;4(2):179-187.
54. Yamamoto K, de Waard V, Fearns C, Loskutoff DJ. Tissue distribution and regulation of murine von Willebrand factor gene expression in vivo. Blood. 1998;92(8):2791-2801.
55. Brown H, Hien TT, Day N, et al. Evidence of bloodbrain barrier dysfunction in human cerebral malaria. Neuropathol Appl Neurobiol. 1999;25(4):331-340.
56. Brown H, Rogerson S, Taylor T, et al. Blood-brain barrier function in cerebral malaria in Malawian children. Am J Trop Med Hyg. 2001;64(3-4):207-213.
57. Thumwood CM, Hunt NH, Clark IA, Cowden WB. Breakdown of the blood-brain barrier in murine cerebral malaria. Parasitology. 1988;96(Pt 3):579-589.
58. Seydel KB, Kampondeni SD, Valim C, et al. Brain swelling and death in children with cerebral malaria. N Engl J Med. 2015;372(12):1126-1137.
59. Schofield L, Grau GE. Immunological processes in malaria pathogenesis. Nat Rev Immunol. 2005;5(9):722-735.
60. Franke-Fayard B, Janse CJ, Cunha-Rodrigues M, et al. Murine malaria parasite sequestration: CD36 is the major receptor, but cerebral pathology is unlinked to sequestration. Proc Natl Acad Sci USA. 2005;102(32):11468-11473.
61. White NJ, Turner GD, Medana IM, Dondorp AM, Day NP. The murine cerebral malaria phenomenon. Trends Parasitol. 2010;26(1):11-15.
62. Carvalho LJ. Murine cerebral malaria: how far from human cerebral malaria? Trends Parasitol. 2010;26(6):271-272.
63. Hunt NH, Grau GE, Engwerda C, et al. Murine cerebral malaria: the whole story. Trends Parasitol. 2010;26(6):272-274.
64. MacDonald SM, Bhisutthibhan J, Shapiro TA, et al. Immune mimicry in malaria: Plasmodium falciparum secretes a functional histaminereleasing factor homolog in vitro and in vivo. Proc Natl Acad Sci USA. 2001;98(19):10829-10832.
65. Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cellderived ultralarge von Willebrand factor multimers under flow. Blood. 2004;104(1):100-106.
66. Bonnefoy A, Daenens K, Feys HB, et al. Thrombospondin-1 controls vascular platelet recruitment and thrombus adherence in mice by protecting (sub) endothelial VWF from cleavage by ADAMTS13. Blood. 2006;107(3):955-964.
67. Cao W, Krishnaswamy S, Camire RM, Lenting PJ, Zheng XL. Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc Natl Acad Sci USA. 2008;105(21):7416-7421.
68. Crawley JT, Lam JK, Rance JB, Mollica LR, O'Donnell JS, Lane DA. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood. 2005;105(3):1085-1093.
69. Studt JD, Kremer Hovinga JA, Antoine G, et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood. 2005;105(2):542-544.
70. Chen J, Hobbs WE, Le J, Lenting PJ, de Groot PG, López JA. The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma. Blood. 2011;117(13):3680-3683.
71. de Souza JB, Hafalla JC, Riley EM, Couper KN. Cerebral malaria: why experimental murine models are required to understand the pathogenesis of disease. Parasitology. 2010;137(5):755-772.
72. Shavit JA, Manichaikul A, Lemmerhirt HL, Broman KW, Ginsburg D. Modifiers of von Willebrand factor identified by natural variation in inbred strains of mice. Blood. 2009;114(26):5368-5374.
73. Banno F, Kokame K, Okuda T, et al. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood. 2006;107(8):3161-3166.
74. Zhou W, Bouhassira EE, Tsai HM. An IAP retrotransposon in the mouse ADAMTS13 gene creates ADAMTS13 variant proteins that are less effective in cleaving von Willebrand factor multimers. Blood. 2007;110(3):886-893.
75. Rondaij MG, Bierings R, Kragt A, van Mourik JA, Voorberg J. Dynamics and plasticity of Weibel-Palade bodies in endothelial cells. Arterioscler Thromb Vasc Biol. 2006;26(5):1002-1007.
76. Fiedler U, Reiss Y, Scharpfenecker M, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med. 2006;12(2):235-239.
77. Bernardo A, Ball C, Nolasco L, Choi H, Moake JL, Dong JF. Platelets adhered to endothelial cellbound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress. J Thromb Haemost. 2005;3(3):562-570.
78. Pendu R, Terraube V, Christophe OD, et al. P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor. Blood. 2006;108(12):3746-3752.